ATE290000T1 - Muscarinagonisten - Google Patents

Muscarinagonisten

Info

Publication number
ATE290000T1
ATE290000T1 AT01932682T AT01932682T ATE290000T1 AT E290000 T1 ATE290000 T1 AT E290000T1 AT 01932682 T AT01932682 T AT 01932682T AT 01932682 T AT01932682 T AT 01932682T AT E290000 T1 ATE290000 T1 AT E290000T1
Authority
AT
Austria
Prior art keywords
muscarinagonists
Prior art date
Application number
AT01932682T
Other languages
English (en)
Inventor
Carl-Magnus A Andersson
Bo Lennart M Friberg
Niels Skjaerbaek
Tracy Spalding
Allan K Uldam
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of ATE290000T1 publication Critical patent/ATE290000T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01932682T 2000-04-28 2001-04-27 Muscarinagonisten ATE290000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20079100P 2000-04-28 2000-04-28
PCT/US2001/013561 WO2001083472A1 (en) 2000-04-28 2001-04-27 Muscarinic agonists

Publications (1)

Publication Number Publication Date
ATE290000T1 true ATE290000T1 (de) 2005-03-15

Family

ID=22743194

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932682T ATE290000T1 (de) 2000-04-28 2001-04-27 Muscarinagonisten

Country Status (19)

Country Link
US (3) US6627645B2 (de)
EP (1) EP1278741B1 (de)
JP (2) JP4119126B2 (de)
KR (2) KR100901221B1 (de)
CN (3) CN101016296A (de)
AR (1) AR028385A1 (de)
AT (1) ATE290000T1 (de)
AU (2) AU2001259190B2 (de)
BR (1) BR0110420A (de)
CA (1) CA2407594A1 (de)
DE (1) DE60109148T2 (de)
ES (1) ES2238437T3 (de)
MX (1) MXPA02010550A (de)
NO (1) NO326106B1 (de)
NZ (1) NZ521978A (de)
RU (1) RU2269523C2 (de)
TW (3) TWI310035B (de)
WO (1) WO2001083472A1 (de)
ZA (1) ZA200208504B (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310035B (en) * 2000-04-28 2009-05-21 Acadia Pharm Inc Muscarinic agonists
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
RU2288919C2 (ru) 2001-10-02 2006-12-10 Акадиа Фармасьютикалз, Инк. Производные бензимидазолидинона в качестве агентов мускариновых рецепторов
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
AU2002359875B2 (en) * 2001-12-28 2009-01-08 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
JP2006504660A (ja) 2002-07-31 2006-02-09 ユーロ−セルティーク エス．エイ． アリール置換ベンゾイミダゾール類およびナトリウムチャネルブロッカーとしてのそれらの使用
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
CN1777425A (zh) * 2003-03-28 2006-05-24 阿卡蒂亚药品公司 用于疼痛控制的毒蕈碱性m1受体激动剂
US7592352B2 (en) 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
US7714009B2 (en) 2003-10-31 2010-05-11 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
GB0328295D0 (en) * 2003-12-05 2004-01-07 Muscagen Ltd Therapeutic compounds
BRPI0417749A (pt) * 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
WO2006019497A2 (en) 2004-06-17 2006-02-23 Neurocrine Biosciences, Inc. Sleep-inducing compounds and methods related thereto
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
BRPI0517438A (pt) * 2004-10-25 2008-10-07 Lilly Co Eli composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
JP2008521821A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
US7786308B2 (en) * 2005-03-28 2010-08-31 Vertex Pharmaceuticals Incorporated Muscarinic modulators
WO2006124897A2 (en) * 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101252935A (zh) * 2005-08-24 2008-08-27 莱西肯医药有限公司 吡咯并吡啶，吡咯并嘧啶和吡唑并吡啶化合物，包含它们的组合物及它们的使用方法
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2275096A3 (de) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
JP2011515403A (ja) * 2008-03-21 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション キノリジジノンｍ１受容体ポジティブアロステリックモジュレータ
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2408448A4 (de) * 2009-03-18 2012-09-19 Univ Leland Stanford Junior Verfahren und zusammensetzungen zur behandlung von flaviviridae-virusinfektionen
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
TR201906779T4 (tr) 2011-05-12 2019-05-21 Proteostasis Therapeutics Inc Proteostaz regülatörleri.
WO2013014052A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
JP6216387B2 (ja) 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
SMT201700378T1 (it) 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
JP2016513677A (ja) * 2013-03-15 2016-05-16 アカディア ファーマシューティカルズ インコーポレイテッド ムスカリンアゴニスト
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3233799B1 (de) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamin-d2-rezeptor-liganden
EP3233077B1 (de) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamin-d2-rezeptor-liganden
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP6368270B2 (ja) * 2015-04-02 2018-08-01 株式会社エヌ・ティー・エイチ モニエロサイドａ及びその誘導体、又はそれを有効成分として含有する医薬用組成物、健康食品又は化粧品
AU2016315881B2 (en) * 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
BR112018016689A2 (pt) 2016-02-16 2019-02-12 Univ Vanderbilt moduladores alostéricos positivos do receptor muscarínico de acetilcolina m1
GB201616839D0 (en) * 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2019241467A1 (en) 2018-06-13 2019-12-19 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2020086864A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2020181035A1 (en) * 2019-03-06 2020-09-10 Barry university Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (de) 2021-04-12 2024-02-21 Incyte Corporation Kombinationstherapie mit einem fgfr-inhibitor und einem auf nectin-4 abzielenden mittel
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US20250064833A1 (en) 2021-12-13 2025-02-27 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
JP2026524104A (ja) * 2023-06-28 2026-07-17 サイロ プロプリエタリー リミテッド 化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3412097A (en) * 1964-09-07 1968-11-19 Koninklijke Pharma Fab Nv Indole derivatives
BE669095A (de) 1964-09-07
US3417087A (en) * 1965-12-27 1968-12-17 Research Corp 3(aminopropionyl)benzothiophenes
US3855242A (en) * 1967-12-15 1974-12-17 Aspro Nicholas Ltd Benzo{8 b{9 thienyl-alkyl-guanidines
FR2305982A1 (fr) * 1975-04-03 1976-10-29 Innothera Lab Sa Nouvelles benzothienyl amino (propyl et butyl) cetones, leur procede de preparation et leur application en therapeutique
US4458075A (en) 1982-04-09 1984-07-03 Hoechst-Roussel Pharmaceuticals Inc. 6-Fluoro-3-[3-(1-heterocyclo)propyl]-1,2-benzisoxazoles
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
HU225055B1 (en) * 1990-10-15 2006-05-29 Pfizer Indole derivatives, their intermediates, process for production them and pharmaceutical compositions containing the compounds
DE4039631A1 (de) 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination
US5143923B1 (en) 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
JP3462501B2 (ja) * 1992-11-23 2003-11-05 アベンティス・ファーマスーティカルズ・インコーポレイテツド 置換された３−（アミノアルキルアミノ）−１，２−ベンゾイソキサゾールおよび関連化合物
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
FR2735129B1 (fr) * 1995-06-07 1997-07-11 Adir Nouveaux derives de l'indole, de l'indazole et du benzisoxazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2751647B1 (fr) 1996-07-25 1998-09-11 Synthelabo Derives de benzimidazole, leurs preparations et leurs applications en therapeutique
US5900312A (en) 1996-11-08 1999-05-04 W. L. Gore & Associates, Inc. Integrated circuit chip package assembly
DE19725664A1 (de) 1997-06-18 1998-12-24 Merck Patent Gmbh 3-Benzylpiperidine
FR2803298A1 (fr) * 1999-12-30 2001-07-06 Adir Nouvelles urees lineaires ou cycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2804429B1 (fr) * 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI310035B (en) * 2000-04-28 2009-05-21 Acadia Pharm Inc Muscarinic agonists

Also Published As

Publication number Publication date
CN1439002A (zh) 2003-08-27
DE60109148T2 (de) 2006-01-05
CN101016296A (zh) 2007-08-15
NO20025115L (no) 2002-12-19
US20050113357A1 (en) 2005-05-26
KR20030005306A (ko) 2003-01-17
HK1058196A1 (en) 2004-05-07
NZ521978A (en) 2004-10-29
ES2238437T3 (es) 2005-09-01
US6627645B2 (en) 2003-09-30
DE60109148D1 (de) 2005-04-07
EP1278741A1 (de) 2003-01-29
NO326106B1 (no) 2008-09-22
TW200505900A (en) 2005-02-16
KR100901221B1 (ko) 2009-06-08
JP2008133297A (ja) 2008-06-12
CA2407594A1 (en) 2001-11-08
CN1249051C (zh) 2006-04-05
WO2001083472A1 (en) 2001-11-08
MXPA02010550A (es) 2004-05-17
JP2003531901A (ja) 2003-10-28
US20070155795A1 (en) 2007-07-05
ZA200208504B (en) 2004-01-22
KR20070086548A (ko) 2007-08-27
US7238713B2 (en) 2007-07-03
TWI310035B (en) 2009-05-21
AU2001259190B2 (en) 2007-01-25
CN1814596A (zh) 2006-08-09
RU2269523C2 (ru) 2006-02-10
TW200505901A (en) 2005-02-16
AR028385A1 (es) 2003-05-07
JP4119126B2 (ja) 2008-07-16
AU5919001A (en) 2001-11-12
BR0110420A (pt) 2003-07-01
US20020037886A1 (en) 2002-03-28
NO20025115D0 (no) 2002-10-24
TWI306859B (en) 2009-03-01
EP1278741B1 (de) 2005-03-02

Similar Documents

Publication Publication Date Title
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATA2932001A (de) Schneefräse
DE50108963D1 (de) Schlauchklemme
DE50106867D1 (de) Kugelgelenk
DE50108226D1 (de) Vordralldüsenträger
DE50102988D1 (de) Bodenwischer
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
DE50104651D1 (de) Fahrzeugfaltverdeck
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE10192638T1 (de) Bohrstangenladevorrichtung
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50011511D1 (de) Blowby-Heizung
DE50100817D1 (de) Kugelgelenk
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE50112451D1 (de) Befestigunsvorrichtung
DE50007634D1 (de) Kardioplegieballonkatheter
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
DE10195909T1 (de) Viehfüttervorrichtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties